secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001564590-22-019665
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent reports Q1 net loss $17.5M; cash $272.7M; ALK trial expected Q2 2022
-----------------------------------------------------------------------------

- Net loss of $17.5M ($0.36 diluted EPS); R&D expenses $12.7M, G&A $5.0M.
- Cash, cash equivalents and marketable securities of $272.7M; expected to fund operations into 2024.
- IND for NVL-655 (ALK) cleared; ALKOVE-1 Phase 1/2 trial anticipated to begin Q2 2022.
- On track to select two additional development candidates in 2022 (ALK resistance mutations and HER2 exon 20).
- Appointed Anna Protopapas as Chair of Board of Directors in March 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000156459022019665/0001564590-22-019665-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000156459022019665/nuvl-8k_20220512.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-019665

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer